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ABSTRACT 
Objective: Objective of present paper was to perform comparative Molecular Field Analysis on 4(3H) Quinazolinone derivatives for the 
Development of Potential Antimicrobial Agents. 
Method: 4(3H)-quinazolinone is one of the most frequently studied heterocyclic moiety possessing wide range of biological activities. Three 
dimensional quantitative structure activity analysis (3D QSAR) has been carried out on some already reported 4(3H)-quinazolinone derivatives 
to explore the structural requirements for antifungal and antibacterial activities. QSAR models were generated with comparative molecular 
field analysis (CoMFA) using partial least square (PLS) method. CoMFA descriptors were calculated on aligned structures to understand the 
steric and electrostatic field contribution on the biological activity.  
Result and Discussion: The generated CoMFA models for antifungal activity showed a cross-validation coefficient (q2) of 0.578, non-cross 
validation coefficient (r2) of 0.923 and standard error of 0.0177. The predictive ability of the model was validated using external validation with 
predictive factor (r2pred) of 0.94 for antifungal activity. The significant statistical parameters indicated the reliability and good predictive power 
of the developed model. The 3D contour maps generated from CoMFA models were analyzed for key structural requirements for improved 
activity.  
Conclusion: This study will help to further optimize quinazoline-4(3H)-one derivatives for antimicrobial activities.  
Keywords: 4(3H)-quinazolinones; 3D QSAR; Comparative molecular field analysis (CoMFA); antifungal activity; antibacterial activity.  
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INTRODUCTION 
One of the most frequently encountered heterocycles in 
medicinal chemistry is 4(3H)-quinazolinone with wide 
applications including anticonvulsant, sedative, tranquilizer, 
analgesic, antimicrobial, anesthetic, anticancer, 
antihypertensive, anti-inflammatory, diuretic and muscle 
relaxant properties. Over the years various substitution have 
been made at position 2and 3 to get potent antimicrobial 
agents. In our earlier work we synthesized a hybrid series of 
3-[5-substituted phenyl-1,3,4-thiadiazole-2-yl]-2-styryl 
quinazoline-4(3H)-one with potent antimicrobial activity1. 
Quantitative structure-activity relationship (QSAR) 
methodology is an essential tool to predict the relationship 
between the structure of molecules and their biological 
activities which is essential for the drug design and 
discovery. The variation in biological activities with in a 
series can be explained with the changes in the molecular 
features of compounds. The developed model through QSAR 
studies can also be used to predict the activities of novel 
molecules prior to their synthesis. It can be used to 
understand the structural requirements for potent biological 
activity or to modify the existent biological activity of a 
particular molecule.Thus QSAR study is a very useful tool in 
modern drug discovery process to get better insight into 
structure activity relationships. In 3D QSAR methods 
comparativemolecular field analyses (CoMFA) can be 
appliedto gain insights into how steric, electrostatic 
interactions influence activities2. 
In present study we have performed 3D-QSAR based 
comparative molecular field analysis (CoMFA) to understand 
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structural patterns requirements on the compound for 
potent the development of antimicrobial agents. 
EXPERIMENTAL 
Dataset  
A set of 42 quinazoline-4(3H)-one derivatives and their 
corresponding antifungal activity (MIC in µg/ml) data in 
Aspergillus nigers (MTCC-1344) and antibacterial activity 
(MIC in µg/ml) data in Bacillus subtilis (MTCC-619) reported 
by Jatav et al., were selected1 and used for the development 
of 3D QSAR CoMFA models. The dataset was randomly 
divided into the training set of 34 compounds (80%) to 
generate the 3D QSAR model, and the test set of 8 
compounds (20%) to verify the predictive ability of the 
model. The biological activities of the compounds were 
represented as pMIC (-logMIC) which has been used as 
dependent variables. To get a good model the selection of 
training set and the test set was carried out in such a way 
that both the sets contain structurally diverse compounds 
and activities of all range3. All the structures in the dataset 
were sketched in ChemDraw Ultra 8.0 software. 
 
Table 1: Chemical structures quinazoline-4(3H)-one derivatives and their antifungal and antibacterial activities. 
NN
S
N
N
O
R
Ar
 
Sl.N
o. 
Compound 
codes 
Ar R Antifungal activity MIC 
in µg/ml 
Antibacterial activity 
MIC in µg/ml 
A. nigers (MTCC-1344) B. subtilis (MTCC-619) 
1 4a -C6H5 -C6H5 16.86 8.42 
2 4b -C6H5 p-OCH3C6H4 17.92 7.08 
3 4c -C6H5 p-CH3C6H4 14.16 6.46 
4 4d -C6H5 p-ClC6H4 15.18 7.89 
5 4e -C6H5 m-ClC6H4 15.72 7.45 
6 4f -C6H5 -CH=CHC6H4 14.62 9.92 
7 4g p-OCH3C6H4 -C6H5 15.05 10.31 
8 4h p-OCH3C6H4 p-OCH3C6H4 17.16 6.22 
9 4i p-OCH3C6H4 p-CH3C6H4 17.02 5.46 
10 4j p-OCH3C6H4 p-ClC6H4 16.45 6.91 
11 4k p-OCH3C6H4 m-ClC6H4 13.86 6.72 
12 4l p-OCH3C6H4 -CH=CHC6H4 14.08 10.49 
13 4m p-CH3C6H4 -C6H5 15.87 7.99 
14 4n p-CH3C6H4 p-OCH3C6H4 16.63 5.12 
15 4o p-CH3C6H4 p-CH3C6H4 14.12 10.22 
16 4p p-CH3C6H4 p-ClC6H4 14.02 9.11 
17 4q p-CH3C6H4 m-ClC6H4 13.70 8.21 
18 4r p-CH3C6H4 -CH=CHC6H4 16.62 7.94 
19 VJ19 p-ClC6H4 -C6H5 11.32 8.32 
20 VJ20 p-ClC6H4 p-OCH3C6H4 12.43 4.65 
21 VJ21 p-ClC6H4 p-CH3C6H4 12.47 5.46 
22 VJ22 p-ClC6H4 p-ClC6H4 11.88 6.46 
23 VJ23 p-ClC6H4 m-ClC6H4 12.48 7.64 
24 VJ24 p-ClC6H4 -CH=CHC6H4 11.76 7.63 
25 VJ25 m-ClC6H4 -C6H5 12.42 6.43 
26 VJ26 m-ClC6H4 p-OCH3C6H4 12.68 7.48 
27 VJ27 m-ClC6H4 p-CH3C6H4 13.34 8.21 
28 VJ28 m-ClC6H4 p-ClC6H4 12.42 7.66 
29 VJ29 m-ClC6H4 m-ClC6H4 11.76 7.68 
30 VJ30 m-ClC6H4 -CH=CHC6H4 12.32 10.30 
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31 VJ31 
N
 
 
-C6H5 
11.90 7.40 
32 VJ32 
N
 
 
p-OCH3C6H4 
12.24 8.32 
33 VJ33 
N
 
 
p-CH3C6H4 
12.42 9.42 
34 VJ34 
N
 
 
p-ClC6H4 
11.48 8.47 
35 VJ35 
N
 
 
m-ClC6H4 
10.54 7.08 
36 VJ36 
N
 
 
-CH=CHC6H4 
10.94 10.75 
37 VJ37 -CH=CHC6H4 -C6H5 13.43 7.48 
38 VJ38 -CH=CHC6H4 p-OCH3C6H4 12.48 6.40 
39 VJ39 -CH=CHC6H4 p-CH3C6H4 14.90 7.16 
40 VJ40 -CH=CHC6H4 p-ClC6H4 15.26 9.21 
41 VJ41 -CH=CHC6H4 m-ClC6H4 15.67 8.47 
42 VJ42 -CH=CHC6H4 -CH=CHC6H4 14.82 7.44 
 
Energy minimization of compounds 
To get best conformers of each molecule the Sybyl X-2.1.1 
software package was used for energy minimization. The 
energy minimizations were done using Tripos force field and 
the Powell gradient algorithm with a convergence criterion 
of 0.05 kcal/(mol*Å) and maximum iteration count of 1000. 
The partial atomic charges were calculated using Gasteiger-
Huckel method3. 
Molecular Alignment rules for CoMFA modeling 
Molecular alignment is one of the most essential steps for the 
generation of the best CoMFA models. There are various 
approaches suggested for molecular alignment in the 
literature. Some of them are: 
Align Database alignment (Maximum Common Structure 
based alignment): This alignment is done based on maximum 
common structure of molecules using the most active 
molecule in the dataset as template. 
Distill Rigid Alignment: Molecules are aligned according to 
their electrostatic and steric field on the template molecule. 
 
Figure 1: Distill rigid molecular alignment of molecules in 
the dataset. 
Multifit: A number of attributes like electrostatic and steric 
fields, particular atom or groups, etc. can be used for 
alignment of the molecules to the template molecule by 
flexible fitting. 
In the present study Align database and Distill Rigid 
alignment type were used. The template molecule used was 
the most potent molecule in the dataset. 
CoMFA studies 
In the CoMFA method steric and electrostatic fields were 
calculated using Lennard-Jones and Coulombic potentials 
respectively. A 3D cubic lattice with a grid spacing of 2.0 Å, 
was generated automatically to surround the aligned 
molecules in all directions. These grid points were generated 
using the Tripos force field, a sp3 carbon atom probe with a 
Van der Waals radius of 1.52 Å, and a charge of +1.00 
(default probe atom in Sybyl) to calculate various steric and 
electrostatic fields. The default energy cut off for steric and 
electrostatic fields was 30 kcal/mol. 
Internal Validation and Partial Least Squares (PLS) 
Analysis 
Partial Least Square regression analysis was done on the 
training set to develop the correlation between the QSAR 
(CoMFA) models and biological activity4. The reliability of 
the developed models were evaluated through leave-one-out 
(LOO) internal validation method, which calculates the 
square of the cross-validation coefficient (q2) and the 
optimal number of components (ONC). Other parameters for 
the evaluation of the model are the non-cross-validation 
coefficient (r2) and standard error of estimate (SEE). 
External Validation of the QSAR model 
The predictive ability of developed CoMFA models were 
evaluated using the test set. The predictive factor r2(r2pred)5 
was calculated using the predicted activity of the test set as 
follows: 
r2pred 
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where, SD= sum of squared deviation between the biological 
activity of molecules in the test set and mean biological 
activity of the training set molecules; PRESS= the sum of 
squared deviations between actual and predicted activity 
values for each molecule in the test set 
RESULTS AND DISCUSSION 
The 3D-QSAR models were obtained using a training set of 
34 compounds and a test set of 8 compounds. The statistical 
parameters related to CoMFA models can be found in Table 
2. The best CoMFA models were generated employing a 
partial least square (PLS) analysis, which produced squared 
regression coefficient (r2) and cross-validation coefficient 
(q2). When squared regression coefficient (r2) and cross-
validation coefficient (q2) > 0.5, the model is considered as 
significant one. As shown in Table 2, the best CoMFA model 
for antifungal activity showed q2 of 0.578, r2 of 0.923 and a 
very low standard error of 0.0177. 
 
Table 2: Statistical parameters of the CoMFA models of antifungal and antibacterial activity 
Sl. 
No. 
Activity O
N
C 
q2 r2 r2pred SEE Steric bulk 
desirable (%) 
Steric bulk 
undesirable 
(%) 
Positive 
charge 
desirable 
(%) 
Negative 
charge 
desirable 
(%) 
1 Antifungal 3 0.578 0.923 0.94 0.0177 36.43 27.61 4.71 11.22 
2 Antibacterial 4 0.127 0.878 * 0.0329 30.27 18.44 17.57 13.69 
*as the q2 of the antibacterial model is insignificant, r2pred was not calculated. 
 
The distribution of actual and predicted pMIC for training 
and test set are shown in Figure 2. This showed a good fit 
diagonally. Thus the model is highly significant and can be 
used for further study. But in case of antibacterial activity the 
CoMFA model showed statistically insignificant results, 
having a q2 of -0.127. The actual and predicted antifungal and 
antibacterial activities (pMIC) and their respective residuals 
are shown in Table 3. 
 
Table 3: Actual and predicted Antifungal and Antibacterial (pMIC) activity and their respective residuals. 
Sl. No. Codes Antifungal activities Antibacterial activities 
Actual 
pMIC 
Pred-pMIC Residuals Actual 
pMIC 
Pred-pMIC Residuals 
1 4a -1.2268 -1.2198 0.0070 -0.9253 -0.932 0.0067 
2 4b -1.2533 -1.2487 0.0046 -0.85 -0.8577 0.0077 
3 4c -1.1510 -1.179 0.0280 -0.8102 -0.8388 0.0286 
4 4d -1.1852 -1.1823 0.0029 -0.8970 -0.897 0.0000 
5 4e -1.1964 -1.1842 0.0122 -0.8721 -0.8919 0.0198 
6 4f* -1.1649 -1.1487 0.0162 -0.9965 -0.9599 0.0366 
7 4g# -1.1775 -1.201 0.0235 -1.0132 -0.8787 0.1345 
8 4h# -1.2345 -1.2364 0.0019 -0.7937 -0.814 0.0203 
9 4i -1.2309 -1.2486 0.0177 -0.7371 -0.7305 0.0066 
10 4j -1.2161 -1.205 0.0111 -0.8394 -0.8191 0.0203 
11 4k*# -1.1417 -1.1511 0.0094 -0.8273 -0.918 0.0907 
12 4l -1.1486 -1.1328 0.0158 -1.0207 -1.0116 0.0091 
13 4m -1.2005 -1.1933 0.0072 -0.9025 -0.9049 0.0024 
14 4n -1.2208 -1.1866 0.0342 -0.7092 -0.7143 0.0051 
15 4o -1.1498 -1.1516 0.0018 -1.0094 -0.9667 0.0427 
16 4p -1.1467 -1.1484 0.0017 -0.9595 -0.9682 0.0087 
17 4q -1.1367 -1.1637 0.0270 -0.9143 -0.9153 0.001 
18 4r*# -1.2206 -1.1815 0.0391 -0.8998 -0.917 0.0172 
19 VJ19 -1.0538 -1.0744 0.0206 -0.9201 -0.852 0.0681 
20 VJ20 -1.0944 -1.089 0.0054 -0.6674 -0.6964 0.029 
21 VJ21 -1.0958 -1.1023 0.0065 -0.7371 -0.7364 0.0007 
22 VJ22* -1.0748 -1.0848 0.0100 -0.8102 -0.8221 0.0119 
23 VJ23 -1.0962 -1.0775 0.0187 -0.8830 -0.8824 0.0024 
24 VJ24# -1.0704 -1.0831 0.0127 -0.8825 -0.8945 0.0120 
25 VJ25 -1.0941 -1.0969 0.0028 -0.8082 -0.8547 0.0465 
26 VJ26 -1.1031 -1.1255 0.0224 -0.8739 -0.8169 0.0570 
27 VJ27 -1.1251 -1.1175 0.0076 -0.9143 -0.9574 0.0431 
28 VJ28* -1.0941 -1.0967 0.0026 -0.8842 -0.856 0.0282 
29 VJ29 -1.0704 -1.0833 0.0129 -0.8853 -0.8875 0.0022 
30 VJ30 -1.0906 -1.1055 0.0149 -1.0128 -1.0067 0.0061 
31 VJ31# -1.0755 -1.0697 0.0058 -0.8692 -0.9209 0.0517 
32 VJ32# -1.0877 -1.0668 0.0209 -0.9201 -0.7625 0.1576 
33 VJ33 -1.0941 -1.0601 0.0340 -0.9740 -0.9157 0.0583 
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34 VJ34 -1.0599 -1.0672 0.0073 -0.9278 -0.9434 0.0156 
35 VJ35 -1.0228 -1.0419 0.0191 -0.85 -0.9399 0.0899 
36 VJ36* -1.0390 -1.1501 0.1111 -1.0314 -1.0349 0.0035 
37 VJ37 -1.1280 -1.1394 0.0114 -0.8739 -0.8869 0.0130 
38 VJ38* -1.0962 -1.187 0.0908 -0.8061 -0.8078 0.0017 
39 VJ39 -1.1731 -1.1508 0.0223 -0.8549 -0.8524 0.0025 
40 VJ40*# -1.1835 -1.1538 0.0297 -0.9642 -0.8391 0.1251 
41 VJ41 -1.1950 -1.1698 0.0252 -0.9278 -0.9343 0.0065 
42 VJ42 -1.1708 -1.1695 0.0013 -0.8715 -0.8832 0.0117 
*test set molecule in antifungal CoMFA model; #test set molecule in antibacterial CoMFA model. 
 
 
(A)                                                                  (B) 
Figure 2: Plots of Actual versus Predicted antifungal pMIC values for (A) training (B) test set. 
During calculation of predictive factor r2(r2pred), predicted 
pMIC of two compounds in the test set (code- VJ 36 and VJ 
38) were excluded. It is clear from the Figure 2(B) that these 
two compounds are not in the diagonal line and behaving as 
outliers. The r2pred for antifungal CoMFA model is 0.94 (>0.5) 
which is highly significant, indicating good predictive ability 
of the model. 
The CoMFA contour maps of most potent compound for 
antifungal activity and for antibacterial activity are shown in 
Figure 3 and Figure 4 respectively. The electrostatic contour 
map (Figure 3A for antifungal activity and Figure 4A for 
antibacterial activity) has blue and red regions. The blue 
regions indicate that presence of an electropositive group 
near them may increase the activity. While the red areas 
favors an electronegative group for better activity. In the 
other hand the steric contour map (Figure 3B and Figure 4B, 
for antifungal and antibacterial activity respectively) 
comprises of green and yellow regions. The green areas 
indicate that bulky groups (such as benzene ring) near them 
increase activity. While in the green areas presence of bulky 
groups decrease the activity.  
 
          
(A)                                                                                (B) 
Figure 3: CoMFA contour maps for antifungal activity displayed with most potent compound, VJ35. (A) CoMFA electrostatic 
contour map (blue, electropositive favored; red, electronegative favored); (B) CoMFA steric contour map (green, favored; 
yellow, disfavored). 
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(A)                                                              (B) 
Figure 4: CoMFA contour maps for antibacterial activity displayed with most potent compound, VJ20. (A) CoMFA electrostatic 
contour map; (B) CoMFA steric contour map. 
 
Design of Compounds 
Based on the CoMFA model obtained along with the help of 
contour maps for the antifungal activity several new 
molecules are designed. The chemical structures of the newly 
designed compounds and their predicted pMIC values are 
presented in Table 4.  
The contour maps of the top ranked newly designed eight 
compounds 7, 19 & 4; 15, 14 & 16; 18 & 11, are presented in 
Figure 5, Figure 6 and Figure 7 respectively. The 3D QSAR 
studies reported here, could be used in the further 
modification and optimization of 4(3H)-quinazolinone 
derivatives for improved microbial activities. 
 
Table 4: Designed compounds using CoMFA and their predicted antifungal activity.
NH2C
R2
R1
N
N
O
N
N
S H
 
 
Compound No. R1 R2 Predicted pMIC 
1 -Cl -H -1.1258 
2 -Br -H -1.1172 
3 -NO2 -H -1.1208 
4 -Cl -Cl -1.0805 
5 -Br -Cl -1.1493 
6 -F -Cl -1.1324 
7 -NO2 -Cl -1.0372 
8 -CH3 -Cl -1.1193 
9 -C2H5 -Cl -1.1256 
10 -OCH3 -Cl -1.1311 
11 -OC2H5 -Cl -1.1108 
12 -Cl -NO2 -1.163 
13 -Br -NO2 -1.1233 
14 -F -NO2 -1.0921 
15 -NO2 NO2 -1.0891 
16 -Cl -CH3 -1.0946 
17 -Br -CH3 -1.1287 
18 -Cl -OCH3 -1.1003 
19 -Br -OCH3 -1.0706 
20 -F -OCH3 -1.1458 
21 -NO2 -OCH3 -1.1577 
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(A)                                                                                                  (B) 
        
(C)                                                                                                 (D) 
        
(E)                                                                                         (F) 
Figure 5:CoMFA contour maps with top ranked predicted antifungal activity of designed compounds (A) Steric, (B) 
Electrostatic, contour map of compound 7; (C) Steric, (D) Electrostatic, contour map of compound 19; (E) Steric, (F) 
Electrostatic, contour map of compound 4. 
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(G)                                                           (H) 
         
(I)                                                           (J) 
        
(K)                                                         (L) 
Figure 6: CoMFA contour maps with predicted antifungal activity of designed compound 15, 14, 16. (G) Steric, (H) Electrostatic, 
contour map of compound 15; (I) Steric, (J) Electrostatic, contour map of compound 14; (K) Steric, (L) Electrostatic, contour 
map of compound 16. 
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(M)                                                         (N) 
         
(O)                                                            (P) 
Figure 7: CoMFA contour maps with predicted antifungal activity of designed compound 18, 11. (M) Steric, (N) Electrostatic, 
contour map of compound 18; (O) Steric, (P) Electrostatic, contour map of compound 11. 
 
CONCLUSIONS 
3D QSAR based CoMFA were performed on reported series 
of 4(3H)-quinazolinone derivatives to investigate the spatial 
structural requirements to develop potent and significant 
antimicrobial compounds. The developed CoMFA model for 
antifungal activity was statistically very significant and used 
to design novel compounds. Out of many hypothetical 
compounds designed twenty one compounds were selected 
based on their predicted activity. Based on the information 
derived from the contour maps several new compounds 
were designed and their activities were predicted. The 
authors are planning to synthesize these screened 
compounds. 
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